Since TXA2 is the primary product of COX-1-dependent metabolism of AA, whose biological actions are mediated through the TXA2 receptor (TPR), and because of the limitation associated with aspirin use, including severe gastrointestinal toxicity, bleeding complications, potential individual response, variability, and poor efficacy in some cardiovascular diseases and procedures, new interest has been focused towards additional TXA2-associated drug targets, in particular TXA2 synthase (TS) and the TPR. Here, TPR is linked to cardiovascular disorder.